Pharmaceutical Companies

The new Computational Innovation site will focus on using advanced data science to better understand disease biology and identify biological mechanisms with a higher likelihood of success in drug development.

The collaboration will enhance the company’s ability to analyze complex datasets, identify promising drug candidates, and significantly reduce the time required to bring medications to patients.

The company forecasts overall revenue growth of 2% to 4% in 2026, with operating profit projected between USD 720 million and USD 770 million.

The acquisition will see Saga integrated into Roche’s subsidiary, Foundation Medicine, which focuses on advanced genomic profiling and personalised cancer care.

The approval grants the pharmaceutical giant the right to market Enflonsia across all 27 member states of the European Union, as well as Iceland, Liechtenstein, and Norway.

MyGenius PRO adds to Bruker’s molecular diagnostics portfolio, which includes InGenius, BeGenius, and LiquidArray assays.

Biogen now holds worldwide rights to the investigational therapy, felzartamab, which is currently undergoing Phase 3 clinical trials for several immune-mediated diseases.

The therapy, known as NRTX-1001, uses pluripotent stem cells engineered to regulate brain activity and repair damaged neural networks.

The Phase Ib/II trial will assess safety, tolerability, and early signs of clinical activity. Researchers will combine Boehringer Ingelheim’s investigational T-cell engager, obrixtamig, with Zai Lab’s antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci).

CrossBridge Bio plans to submit an Investigational New Drug (IND) application for CBB-120, positioning the candidate for clinical development.